由生物醫學中心出版。ISSN: 1745 - 6215。《臨床試驗》是一本開放獲取、同行評議的在線期刊，涵蓋隨機對照試驗的所有方面的表現和結果。試驗將試驗并改進創新的方法，以改進關于試驗的交流。我們渴望超越發布傳統的試驗結果文章(盡管這些將包括在內)。我們認為這是一個令人興奮的機會，可以促進科學和試驗報告。在2006年之前，這些試驗被發表為當前心血管醫學的對照試驗(CCTCVM)。所有已發表的CCTCVM文章均可通過試驗網站獲得，并將繼續支持CCTCVM文章網址的引用。所示的影響因素與CCTCVM在2003-4年間發表的文章有關。讓所有的內容都開放獲取，而不保留版權，審判提供了一種方法，使數據既免費提供，又高度可見的世界各地的審判人員;這將有利于你的出版物在同行和社會中的影響。該期刊擁有不受限制的空間，并利用了電子出版的所有技術可能性。到目前為止，期刊主要報道試驗的結果，很少報道為什么以及如何進行試驗。試驗的報告已經限制由作者和編輯,雙方往往只選擇結果測量的一個子集,而后者經常詞限制文章很難溝通進行審判的教訓,更不用說包含足夠的細節的審判。互聯網提供了無限的空間和交互性，我們熱衷于利用這些特性。例如，測試者將能夠提供真實科學記錄所需的細節，并做更多的工作使文章的信息能夠被各種讀者群體理解。他們還將不僅能夠交流所有的結果測量，以及不同的分析和解釋，而且能夠深入地描述他們做了什么和學到了什么。這種直接經驗的分享對提高全世界試驗的質量和開展工作至關重要。

Published by BioMed Central. ISSN: 1745-6215.Trials is an open access, peer-reviewed, online journal that will encompass all aspects of the performance and findings of randomized controlled trials. Trials will experiment with, and then refine, innovative approaches to improving communication about trials. We are keen to move beyond publishing traditional trial results articles (although these will be included). We believe this represents an exciting opportunity to advance the science and reporting of trials. Prior to 2006, Trials was published as Current Controlled Trials in Cardiovascular Medicine (CCTCVM). All published CCTCVM articles are available via the Trials website and citations to CCTCVM article URLs will continue to be supported. The impact factor shown relates to articles published in CCTCVM during 2003-4. Making all its content open access and not retaining copyright, Trials offers a way to make data both freely available and highly visible to trialists worldwide; this will benefit the impact of your publication among peers and society. The journal has unrestricted space and takes advantage of all the technical possibilities available for electronic publishing. To date, journals have focused on reporting the results of trials, with very little coverage of why and how they are conducted. Reports of trials have been restricted both by authors and editors - both parties often select only a subset of the outcomes measured, while the latter often impose word limits on the articles published making it difficult to communicate the lessons learnt from conducting the trial, let alone include adequate details of how the trial was conducted. The Internet offers both unlimited space and interactivity, and we are keen to harness these attributes. For instance, trialists will be able to provide the detail required to be a true scientific record and do more to make the article's message comprehensible to a variety of reader groups. They will also be able to communicate not only all outcome measures, as well as varying analyses and interpretations, but also in-depth descriptions of what they did and what they learnt. This sharing of direct experience is fundamental to improving the quality and conduct of trials worldwide.